Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Advanced BioMedical Technologies Inc. (ABMT)
New York, NY, US
Advanced Biomedical Technologies, Inc., a development stage company, designs, develops, manufactures, and markets biomaterial internal fixation devices. It offers polymer osteosynthesis devices, such as surgical screws, binding wires, rods, and related medical devices for the treatment of orthopedic trauma, sports-related medical treatment, cartilage repair, and related treatments, as well as for reconstructive dental procedures. The company was formerly known as Geostar Mineral Corporation and changed its name to Advanced Biomedical Technologies, Inc. in March 2009. Advanced Biomedical Technologies, Inc. was founded in 2002 and is based in New York, New York.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | +25.00% | +150.00% | +25.00% | +25.00% | -98.98% | -99.38% | -99.69% | -99.95% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%+58.3% ★ Q3'22: -2,843.9% (vs Q3'21)
-
EPS growth Medical - Devices: +28.5%+29.8% ★ Q3'22: +3.6% (vs Q3'21)
-
FCF margin FCF growth · Medical - Devices: +30.9%-281.6% Q3'22: +3,448.3% (vs Q3'21)
-
EBIT margin Medical - Devices: +6.2%-68.2% Q3'22: +2,163.6% (vs Q3'21)
-
ROIC Medical - Devices: +3.3%— Q3'22: +34.8% (vs Q3'21)
-
Share dilution Medical - Devices: 0.0%+0.5% Q3'22: +0.3% (vs Q3'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-41.03× Q3'22: -17.06× (vs Q3'21)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-10-26 | Advanced Biomedical Technologies Inc. | Director | A-Award | A | ABMT Common Stock | 100,000 | 0.07 | 7.3K | 750,000 | — | ↗ |
| 2021-09-23 | Advanced Biomedical Technologies Inc. | Officer | A-Award | A | ABMT Common Stock | 80,000 | 0.12 | 9.4K | 180,000 | — | ↗ |
| 2020-10-30 | Advanced Biomedical Technologies Inc. | Director / Officer | A-Award | A | ABMT Common Stock | 150,000 | 0.15 | 23.0K | 1,050,000 | — | ↗ |
| 2020-03-09 | Advanced Biomedical Technologies Inc. | Officer | — | D | Common Stock | 0 | 0.00 | — | 100,000 | — | ↗ |
| 2019-10-30 | Advanced Biomedical Technologies Inc. | Director / Officer | A-Award | A | ABMT Common Stock | 150,000 | 0.06 | 9.2K | 900,000 | — | ↗ |
| 2018-10-23 | Advanced Biomedical Technologies Inc. | Director / Officer | A-Award | A | ABMT Common Stock | 100,000 | 0.21 | 21.1K | 450,000 | — | ↗ |
| 2016-10-31 | Advanced Biomedical Technologies Inc. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2012-03-08 | Lynch John Thomas Jr | Other | — | D | ABMT Common Stock | 0 | 0.00 | — | 203,058 | — | ↗ |
| 2011-12-08 | Lynch John Thomas Jr | Other | — | D | ABMT Common Stock | 0 | 0.00 | — | 198,825 | — | ↗ |
| 2008-10-01 | YU CHI MING | Director / Officer / 10% Owner | — | D | COMMON STOCK | 0 | 0.00 | — | 5,001,000 | — | ↗ |
| 2008-10-01 | Protskiv Andriy | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2008-01-30 | Protskiv Andriy | Director / Officer / 10% Owner | — | D | Common stock | 0 | 0.00 | — | 5,000,000 | — | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hui Wang | Chief Executive Officer, Controller & Director | 34.6K | female |
| Chi Ming Yu | President, Treasurer, Compliance Officer & Director | — | male |
| John Thomas Lynch Jr. | Chief Officer of Dental Technologies | — | — |
| Kai Gui | Secretary, Chief Financial Officer, Chief Operating Officer & Director | — | male |
| Puyi Sheng | Chief Medical Officer | — | — |
| Shangli Liu | Chairman of Scientific Board & Chief Medical Advisor of Greater China | — | — |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ABMT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
